# US 2026/0234208 A1 · Method for producing a keratin powder from feathers of animal origin, colloidal solution and keratin powder for topical application containing keratin particles, and use of the colloidal solution and the keratin powder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234208 A1
- Document ID: US20260234208A1
- Status: Published application
- Kind: A1
- Application number: 19/153,903
- Filed: 2024-02-06
- Published: 2026-08-13
- Earliest claimed: 2023-02-08
- Assignees: Rigi Therapeutics AG
- Applicants: Rigi Therapeutics AG
- Inventors: Christian SPORN
- Web page: https://patentgrep.com/patent/US20260234208A1

## CPC

- A61K 35/57: Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
- C07K 14/4741: {Keratin; Cytokeratin}
- A23K 10/26: from waste material, e.g. feathers, bones or skin (A23K10/24 takes precedence)
- A23K 20/142: Amino acids; Derivatives thereof
- A23K 20/147: Polymeric derivatives, e.g. peptides or proteins
- A23L 33/17: Amino acids, peptides or proteins
- A23L 33/175: Amino acids
- A61K 8/65: Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 9/1682: {Processes}
- A61K 38/1748: {Keratin; Cytokeratin}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61Q 19/00: Preparations for care of the skin
- A61K 2800/10: General cosmetic use
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The invention relates to a method for producing keratin powder of the protein β-keratin from feathers of animal origin by extracting keratin, filtering the extraction solution and obtaining a colloidal solution, and drying same to form the keratin powder. The invention also relates to a colloidal solution for topical application containing keratin particles of the protein β-keratin and/or agglomerates thereof or a keratin powder containing said keratin particles. The colloidal solution and the keratin powder are used for the production of preparations with therapeutic, diagnostic, preventative or cosmetic purposes for humans and/or animals.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A method for producing keratin particles from feathers of animal origin, in which
(a) an extraction of the beta-keratin protein is carried out in an extraction solution, which triggers chemical denaturation and comprises at least one denaturing agent, at least one base, at least one reducing agent, and at least one buffering agent,
(b) the extraction solution from step a) is subjected to filtration, in which a colloidal solution of keratin particles of the beta-keratin protein is obtained, and
(c) the colloidal solution of keratin particles from step b) is dried by freeze drying, spray drying, vacuum drying, air drying, heat drying, infrared drying, and/or microwave drying to obtain a keratin powder.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the extraction solution has a pH value of 8 to 13.

### Claim 19 (depends on 17)

The method according to claim 17, wherein the at least one denaturing agent is selected from the group consisting of urea, thiourea, guanidine hydrochloride, and sodium dodecyl sulfate (SDS),
and/or
the at least one base is selected from the group consisting of sodium hydroxide and potassium hydroxide,
and/or
the at least one reducing agent is selected from the group consisting of β-mercaptoethanol, cysteamines, cysteines, glutathione, sodium disulfite, sodium sulfide, sodium hydrogen sulfite, sodium dithionite, sodium thiosulfate, dithiothreitol (DTT), thioglycolic acid and its salts, thiourea, tris(carboxyethyl)phosphine (TCEP) and other phosphines, and ammonium chloride,
and/or
the at least one buffering agent is selected from the group consisting of tris(hydroxymethyl)aminomethane, sodium dodecyl sulfate (SDS), Tris/hydrochloric acid (HCl), ethylenediaminetetraacetic acid (Tris-EDTA), potassium chloride-sodium hydroxide (KCl—NaOH), sodium hydrogen carbonate (NaHCO3), and dithiotreitol (Tris-DTT).

### Claim 20 (depends on 17)

The method according to claim 17, wherein the extraction solution comprises at least one oxidizing agent selected from the group consisting of hydrogen peroxide, potassium permanganate, sodium perborate, peroxyacetic acid, and performic acid,
and/or
the extraction solution comprises at least one acid selected from the group consisting of nitric acid, nitrous acid, hypohalous acid, and hyperhalous acid,
and/or
the extraction solution comprises at least one ionic agent selected from the group consisting of 1-butyl-3-methylimidazolium (BMIM) chloride, 1-butyl-3-methylimidazolium (BMIM) bromide, 1-butyl-3-methylimidazolium (BMIM) tetrafluoroborate, and amide chloride.

### Claim 21 (depends on 17)

The method according to claim 17, wherein, during the extraction in step a), at least one of the following steps is carried out:
(a) mechanical comminution by grinding via ultrasound in a frequency range of 20 to 50 hertz or by utilizing a ball mill and/or a cutting mill, wherein the mechanical comminution is carried out to a particle size of 0.1 to 5.0 mm,
(b) thermal denaturation and/or electrochemical denaturation,
(c) precipitation of the extraction solution from step a) which is triggered by a pH change, addition of a co-solvent, and/or a salt,
(d) microbial and enzymatic extraction via
gram-negative bacteria selected from the group consisting of Stenotrophomonas sp., Chrysebacterium sp., Vibrio sp., and mixtures thereof,
gram-positive bacteria, selected from the group consisting of Bacillus sp., Kocuria rosea, and mixtures thereof,
saprophytic and/or parasitic fungi, and/or
a combination thereof,
(e) treatment with microwave radiation, and
(f) electrical explosion and/or supercritical water.

### Claim 22 (depends on 17)

The method according to claim 17, wherein the filtration is carried out via dialysis and/or ultrafiltration.

### Claim 23

A colloidal preparation suitable for topical application comprising keratin particles of the beta-keratin protein.

### Claim 24 (depends on 23)

The colloidal preparation of claim 23, wherein the beta-keratin is in its secondary structure as a β-pleated sheet, and/or agglomerates thereof obtained from feathers of animal origin.

### Claim 25 (depends on 23)

The colloidal preparation according to claim 23, wherein the keratin particles have a particle size in the range of 5 nm to 500 nm, as measured by means of dynamic light scattering.

### Claim 26 (depends on 24)

The colloidal preparation according to claim 24, wherein the feathers of animal origin are selected from the group consisting of feathers from chickens, geese, ducks, turkeys, pheasants, ostriches, rheas, emus, quails, and mixtures thereof.

### Claim 27 (depends on 23)

The colloidal preparation according to claim 23, which comprises additives for stabilization.

### Claim 28 (depends on 27)

The colloidal preparation according to claim 27, wherein the additives are selected from the group consisting of
proteins,
carbohydrates,
polyanionic surfactants,
non-ionic surfactants,
gelling agents,
thickeners,
film formers, and
polymers, and
mixtures thereof.

### Claim 29 (depends on 23)

A keratin powder suitable for topical application produced from the colloidal preparation according to claim 23.

### Claim 30 (depends on 29)

The keratin powder according to claim 29, wherein the keratin particles in the keratin powder have a particle size in the range of 1 to 250 μm, as measured by dynamic light scattering.

### Claim 31 (depends on 23)

A method of treating a human and/or animal for a condition relating to skin, mucous membrane, or epidermal appendage of the human and/or animal, the method comprising applying to the human and/or animal the colloidal preparation according to claim 23.

### Claim 32 (depends on 29)

A method of treating a human and/or animal for a condition relating to skin, mucous membrane, or epidermal appendage of the human and/or animal, the method comprising applying to the human and/or animal the keratin powder according to claim 29.

### Claim 33 (depends on 31)

The method according to claim 31, wherein the colloidal preparation comprises at least one small-molecule and/or biotechnological active ingredient, wherein, the active ingredient is selected from the group consisting of glucocorticoids, calcineurin inhibitors, Janus kinase inhibitors, antibiotics, and/or a protein in and of itself, a fraction protein, peptide, enzyme, antibody, antibody fragment, RNA and/or DNA molecule, and mixtures thereof, or a molecule which represents a target for one of these active ingredients, and/or the colloidal preparation comprises cosmetic active ingredients and excipients selected from the group consisting of amino acids, urea, glycerol, hyaluronic acid, sugars, sugar-like derivatives, extracts or waxes from plants, or parts derived from animals, and mixtures thereof.

### Claim 34 (depends on 31)

The method according to claim 31, wherein the colloidal preparation includes a liquid base, a semi-solid base, or a solid base.

### Claim 35 (depends on 29)

A food supplement, an animal feed, a fertilizer, a plant protection product, a soil protection product, a technical additive, a packaging material, a consumer good, a textile, fiber, or a medical product produced from the keratin powder according claim 29.
